Yoshinori Matsumoto

Medicine & Life Sciences

1. Systemic Lupus Erythematosus 100%
2. Osteoblasts 78%
3. Vasculitis 76%
4. Glucocorticoids 72%
5. Antineutrophil Cytoplasmic Antibodies 66%
6. Bone Morphogenetic Proteins 54%
7. Cherubism 51%
8. Cross-Sectional Studies 43%
9. Bone Morphogenetic Protein 2 40%
10. Tankyrases 36%
11. Fibroblast Growth Factor 8 35%
12. Registries 35%
13. Granulomatosis with Polyangiitis 34%
14. Aldosterone 33%
15. Bone and Bones 32%
16. Takayasu Arteritis 28%
17. Transcription Factors 27%
18. Phosphorylation 26%
19. Ubiquitin 26%
20. Ubiquitin-Protein Ligases 26%
21. Osteoclasts 26%
22. Protein-Tyrosine Kinases 25%
23. Prednisolone 25%
24. Nephritis 25%
25. Antibodies 24%
26. Remission Induction 24%
27. Ligases 23%
28. Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 23%
29. Bone Morphogenetic Protein Receptors 22%
30. Estrogens 22%
31. Tumor Necrosis Factor-alpha 22%
32. Cytokines 22%
33. Cyclophosphamide 22%
34. Confidence Intervals 22%
35. Cohort Studies 21%
36. Growth Differentiation Factor 10 21%
37. Recurrence 21%
38. Catenins 21%
39. Ulcerative Colitis 20%
40. Rheumatoid Arthritis 20%
41. Rare Diseases 20%
42. Serratia marcescens nuclease 20%
43. Breast Neoplasms 20%
44. Prospective Studies 20%
45. Osteogenesis 20%
46. Kidney 19%
47. Therapeutics 19%
48. Bone Morphogenetic Protein 6 19%
49. Cluster Analysis 19%
50. Carrier Proteins 18%